U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07823790) titled 'ONO-4915 in Patients With Primary Sjogren's Disease' on Sept. 03.
Brief Summary: To evaluate the efficacy and safety of ONO-4915 in patients with primary Sjogren's disease
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Sjogren's Disease
Intervention:
DRUG: ONO-4915
Subcutaneous administration
DRUG: Placebo
Subcutaneous administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ono Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....